Cubist Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 43   

Articles published

CBST 75.65 +0.69 (0.92%)
price chart
Cubist announces results from CB-5945 Phase 2 studies on chronic non-cancer ...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that the results from the Phase 2 studies of CB-5945 (formerly ADL5945) in patients with chronic non-cancer pain and opioid-induced constipation (OIC) will be presented at the 31st Annual ...
Related articles »  
Ra Pharma Pours $8.6M Into Discovery Tech and New Rare-Disease Drug
Today Ra Pharmaceuticals CEO Doug Treco will make a presentation at a conference in Las Vegas that will cap off the Cambridge, MA-based company's weeklong unveiling. On May 16, Ra announced it had closed an $8.6 million tranche of its $27 million ...
Theraclone Passes First Clinical Test with Flu-Fighting Antibody
The Seattle-based biotech company is announcing today that it passed its first clinical trial with an antibody drug designed to fight a wide variety of flu strains.
Related articles »  
Genomic Health, OncoMed Team Up on Personalized Cancer Drug Work
Cancer drugmakers and diagnostics companies rarely find ways to work together early in the product development process, because corporate priorities, budgets and timelines rarely match up.
Related articles »  
Buying SD's Ortiva Wireless Adds Video Optimization to Allot's Tools
In response to a question about Ortiva's local operations, Zionts says the company plans to keep its office in University City post-acquisition, and will likely grow beyond its current 41 employees.
Related articles »  
Vertex Shares Drop on Mistake in Cystic Fibrosis Drug Data
Vertex Pharmaceuticals saw its stock rocket on news earlier this month that its two-drug combo treatment for cystic fibrosis showed a strong benefit in a clinical trial, but the stock is coming back down now that Vertex has come forward to report on a ...
Related articles »  
Ember CEO: Silicon Labs Acquisition for $72M Is �Right Thing for the Company�
One, �This was more than a fair deal financially,� he says, in terms of the multiple of the company's revenue. Two, he says, �This is also about the employees and the potential, and it's the right thing for the company.� And three, he says, the firm's ...
Related articles »  
Who's on Biotech's Endangered Species List? Mid-Sized Drugmakers
�If you are a Big Pharma company facing a patent cliff, you really have a huge revenue gap to fill, and small companies don't really help you.
Related articles »  
Antibiotic R&D is in Trouble: Here's One Way to Fix It
It's hard to nail down that number for sure, but that's according to Mike Bonney, the CEO of Lexington, MA-based antibiotic developer Cubist Pharmaceuticals (NASDAQ: CBST), who has good reason to study the competition. The three big companies left in ...
Related articles »  
iPierian Zeroes In on Antibodies for Alzheimer's, Neurodegeneration
The company is now zeroing in on making antibody drugs for neurodegenerative diseases like Alzheimer's, which are affected by the Tau protein and the Complement biological pathway.
Related articles »